ESC 365 - Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study

ESC Premium Access

Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study

Session: Novel therapeutic targets in hypertrophic cardiomyopathy

Topic: Pharmacotherapy

Speaker: Professor A. Wang (Durham, US)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Andrew Wang

Duke University Medical Center, Durham (United States of America)

0 follower

4 more presentations in this session

State of the Art in the treatment of hypertrophic cardiomyopathy

Speaker: Professor I. Olivotto (Florence, IT)

Earlier surgical myectomy vs. waiting for a Class I indication is associated with improved long-term survival in symptomatic hypertrophic obstructive cardiomyopathy patients

Speaker: Doctor M. Desai (Cleveland, US)

A novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)

Speaker: Doctor G. Norrish (London, GB)

Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.

Speaker: Professor J. Veselka (Prague, CZ)

Access the full session

Novel therapeutic targets in hypertrophic cardiomyopathy

Speakers: Professor A. Wang, Professor I. Olivotto, Doctor M. Desai, Doctor G. Norrish, Professor J. Veselka

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources